Despite a decline in overall senior housing M&A activity from 2022 to 2023, nonprofit M&A is pacing for a record year.[1] Many of the same market conditions that cooled overall M&A activity — such as increasing interest rates, tightened lending requirements and operational uncertainty — appear to be causing a surge in nonprofit affiliations,
Latest from The Healthcare Investor - Page 32
Private Equity in Healthcare – An Updated Review of Selected Niche Investment Areas
Since mid-2022, the macro acquisition environment has faced the challenges of inflation and increasing interest rates, among a variety of other headwinds. Global deal flow is down from its 2021 peak. Yet, as this white paper will explain at a granular level, private equity investment in healthcare companies remains a viable and, in some cases,
SK Capital Closes Fund With $800 Million
SK Capital Partners has announced it has closed its latest fund with $800 million in commitments.
The new fund, SKCP Catalyst Fund II, was oversubscribed. It will focus on buyout investments that generally require initial committed equity capital of up to $100 million.
SK Capital Partners, based in New York, is a private equity
Healthcare & Life Sciences Private Equity Deal Tracker: WM Partners Acquires Allergy Research Group
WM Partners recently announced it had acquired Allergy Research Group (ARG) from Kikkoman Corp.
ARG, founded in 1979 and based in South Salt Lake, Utah, sells hypoallergenic supplements focused on addressing condition-specific issues to healthcare practitioners.
WM Partners, based in Aventura, Fla., is a middle-market private equity firm. Founded in 2015, the firm
Audax Closes Two Funds With $7.8 Billion
Audax Private Equity recently announced it closed two new funds with a combined $7.8 billion.
Audax Private Equity Fund VII was oversubscribed, hitting its hard cap of $5.25 billion.
Audax Private Equity Origins Fund I closed with $774 million, exceeding its initial target. This fund is the firm’s first lower middle market strategy.
When combined
Comvest Closes New Fund at $2 Billion
Comvest Partners has announced it has closed its latest fund at $2 billion.
The new fund, Comvest Credit Partners VI, exceeded its initial target of $1.7.
Comvest, based in West Palm Beach, Fla., is a middle-market private equity and credit investing firm. Its private equity strategy is to pursue control investments in multiple industries,
Healthcare & Life Sciences Private Equity Deal Tracker: TPG Acquires Nextech From Thomas H. Lee for $1.4 Billion
TPG has announced it has acquired Nextech from Thomas H. Lee Partners (THL) for $1.4 billion.
Nextech, based in Tampa, Fla., is a provider of clinical and administrative healthcare technology solutions for specialty physician practices. Founded in 1997, the company states it services more than 11,000 physicians in dermatology, ophthalmology, orthopedics, plastic surgery and med spa.
TPG is investing
Healthcare & Life Sciences Private Equity Deal Tracker: TT Capital Partners Acquires Pyx Health
TT Capital Partners (TTCP) has made a majority growth investment in Pyx Health, according to a news release.
Pyx Health, based in Tucson, Ariz., is the developer of a solution designed to address loneliness and social isolation. Founded in 2017, the company works with major payers as well as government, employer and community
Women in PE to Know: Ewelina Woloszyn
McGuireWoods has long been an avid supporter of the advancement of professional women. As part of our initiative seeking to expand the leadership of women in private equity, we are continuing our series of profiling women leaders in private equity. We are hopeful that this series will serve to inspire other women to pursue their
Healthcare & Life Sciences Private Equity Deal Tracker: Thoma Bravo Invests in Bluesight
Thoma Bravo has announced it has completed a growth investment in Bluesight.
Bluesight, based in Alexandria, Va., is a developer of software supporting the pharmacy supply chain. Founded in 2011, the company’s solutions include those for inventory management, controlled substance diversion prevention and medication purchasing.
Thoma Bravo, with offices in Chicago and San